FTC Orders Illumina to Divest Grail Citing Likely Competitive Harm
- April 07, 2023
The Federal Trade Commission (FTC) is requiring genetic sequencing firm Illumina Inc. to divest cancer detection company Grail, after finding the combination of the two companies was likely to substantially lessen competition in the market for multi-cancer detection tests (MCED).
ARTICLE TAGS
You must be logged in to access this content.